Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Combination therapy effective against heart disease
Crestor has already been shown to be the most effective of the statins (cholesterol lowering medicines) at reducing “bad” cholesterol or LDL-C, enabling most patients with high cholesterol
Crestor has already been shown to be the most effective of the statins (cholesterol lowering medicines) at reducing “bad” cholesterol or LDL-C, enabling most patients with high cholesterol
The complaint filed in US District Court in the Eastern District of Texas, Marshall Division, says the package insert that came with Ortho Evra was misleading and in
The trial tested those who underwent hernia repair surgery. The trial results indicate that LidoPAIN did not achieve a statistically significant effect relative to placebo with respect to
In the study of a large animal model, stoppage of the heart was induced in two groups for about 18 minutes while either a modified AT-101 motion platform
Acute porphyria is designated as an orphan disease by the FDA. Panhematin is the only FDA-approved therapy for acute porphyria, which makes the therapy vital for the treatment
The data demonstrated greater potency and specific activation of the immune response when HspE7 was combined with either of the two adjuvants studied. “These data suggest that combining
The plan consists of three phase III efficacy trials, the first of which is currently ongoing in knee osteoarthritis in the US, with an additional, similarly designed knee
Heart disease patients who were at a very high risk for having a second heart attack and took Lipitor had a 46% reduction in the risk of a
The primary aim of the trial was to assess efficacy by comparing the effectiveness of rhThrombin as a surgical hemostat to the currently approved bovine-derived thrombin, as measured
With this advancement, Amorfix will be committing additional resources to develop an ultra-sensitive blood test for Alzheimer's disease, based upon Amorfix's patent-pending EP technology. Alzheimer's disease is associated